ID   VMM18
AC   CVCL_A737
SY   VMM-18
DR   ATCC; CRL-3229
DR   cancercelllines; CVCL_A737
DR   GEO; GSM1671995
DR   GEO; GSM1672013
DR   GEO; GSM1672046
DR   GEO; GSM1672074
DR   GEO; GSM1672084
DR   GEO; GSM1672096
DR   GEO; GSM1672103
DR   GEO; GSM1672116
DR   GEO; GSM1672124
DR   Wikidata; Q54993264
RX   PubMed=10752474;
RX   PubMed=14871852;
RX   PubMed=15378283;
RX   PubMed=20856146;
RX   PubMed=21654344;
RX   PubMed=26405815;
RX   PubMed=26673621;
CC   Population: Caucasian.
CC   HLA typing: A*03,31/33; B*60 (PubMed=10752474).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26405815).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
ST   Source(s): ATCC=CRL-3229
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 10,12
ST   D16S539: 11
ST   D5S818: 12
ST   D7S820: 9
ST   TH01: 6,9.3
ST   TPOX: 8,10
ST   vWA: 15,18
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_F862 ! VMM18-EBV
SX   Male
AG   45Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 19-12-24; Version: 20
//
RX   PubMed=10752474; DOI=10.1007/s002620050015; PMCID=PMC11037162;
RA   Slingluff C.L. Jr., Colella T.A., Thompson L., Graham D.D.,
RA   Skipper J.C.A., Caldwell J., Brinckerhoff L., Kittlesen D.J.,
RA   Deacon D.H., Oei C., Harthun N.L., Huczko E.L., Hunt D.F.,
RA   Darrow T.L., Engelhard V.H.;
RT   "Melanomas with concordant loss of multiple melanocytic
RT   differentiation proteins: immune escape that may be overcome by
RT   targeting unique or undefined antigens.";
RL   Cancer Immunol. Immunother. 48:661-672(2000).
//
RX   PubMed=14871852; DOI=10.1158/0008-5472.CAN-03-2209;
RA   Hogan K.T., Coppola M.A., Gatlin C.L., Thompson L.W., Shabanowitz J.,
RA   Hunt D.F., Engelhard V.H., Ross M.M., Slingluff C.L. Jr.;
RT   "Identification of novel and widely expressed cancer/testis gene
RT   isoforms that elicit spontaneous cytotoxic T-lymphocyte reactivity to
RT   melanoma.";
RL   Cancer Res. 64:1157-1163(2004).
//
RX   PubMed=15378283; DOI=10.1007/s00262-004-0592-y; PMCID=PMC11032761;
RA   Hogan K.T., Sutton J.N., Chu K.U., Caldwell-Busby J.A., Shabanowitz J.,
RA   Hunt D.F., Slingluff C.L. Jr.;
RT   "Use of selected reaction monitoring mass spectrometry for the
RT   detection of specific MHC class I peptide antigens on A3 supertype
RT   family members.";
RL   Cancer Immunol. Immunother. 54:359-371(2005).
//
RX   PubMed=20856146; DOI=10.1097/CMR.0b013e32833fafb4; PMCID=PMC3229868;
RA   Mikesh L.M., Kumar M., Erdag G., Hogan K.T., Molhoek K.R., Mayo M.W.,
RA   Slingluff C.L. Jr.;
RT   "Evaluation of molecular markers of mesenchymal phenotype in
RT   melanoma.";
RL   Melanoma Res. 20:485-495(2010).
//
RX   PubMed=21654344; DOI=10.1097/CMR.0b013e328343a1d6; PMCID=PMC3131461;
RA   Molhoek K.R., Shada A.L., Smolkin M., Chowbina S., Papin J.,
RA   Brautigan D.L., Slingluff C.L. Jr.;
RT   "Comprehensive analysis of receptor tyrosine kinase activation in
RT   human melanomas reveals autocrine signaling through IGF-1R.";
RL   Melanoma Res. 21:274-284(2011).
//
RX   PubMed=26405815; DOI=10.1371/journal.pone.0138210; PMCID=PMC4583389;
RA   Capaldo B.J., Roller D.G., Axelrod M.J., Koeppel A.F., Petricoin E.F. 3rd,
RA   Slingluff C.L. Jr., Weber M.J., Mackey A.J., Gioeli D., Bekiranov S.;
RT   "Systems analysis of adaptive responses to MAP kinase pathway blockade
RT   in BRAF mutant melanoma.";
RL   PLoS ONE 10:E0138210-E0138210(2015).
//
RX   PubMed=26673621; DOI=10.18632/oncotarget.6548; PMCID=PMC4823068;
RA   Roller D.G., Capaldo B.J., Bekiranov S., Mackey A.J., Conaway M.R.,
RA   Petricoin E.F. 3rd, Gioeli D., Weber M.J.;
RT   "Combinatorial drug screening and molecular profiling reveal diverse
RT   mechanisms of intrinsic and adaptive resistance to BRAF inhibition in
RT   V600E BRAF mutant melanomas.";
RL   Oncotarget 7:2734-2753(2016).
//